Indaptus Therapeutics is trading 10% down at $3.19 after opening-market selling, with no clear company-specific announcement identified for September 21, 2026.
- The decline contrasts with gains across major U.S. indexes, so broader market sentiment does not explain the move.
- A recently announced $24 million private placement involving 20,338,974 shares may contribute to dilution concerns, but no source directly links it to today’s decline.